China News Service, March 13 (Xinhua) According to the website of the National Health Commission, in the recent stage, all units of the national and provincial-level consultation and linkage mechanism for supply guarantees of shortage drugs have focused on ensuring supply and stable prices, strengthening the construction of systems and mechanisms, and strengthening policy coordination. Collaborate with departments to continuously improve the classification and classification response capabilities for shortages of drugs to effectively ensure the drug needs of the public.
Improve the working mechanism and improve the monitoring of shortage drug information in multiple dimensions.
The National Health Commission relies on the national public medical and health institutions’ direct reporting system for drug shortage information and other monitoring situations to carry out monitoring, early warning and regular notifications.
The National Medical Insurance Administration continues to monitor abnormally high prices and distribution data of drugs on the National Shortage Drug List and the Key Monitoring List of Clinically Necessary and Shortage Drugs.
The State Food and Drug Administration continues to collect information on shortages of drug production, supply and production suspension reports.
The Ministry of Industry and Information Technology relies on the production and supply monitoring and early warning platform for shortages of drugs to carry out dynamic monitoring and analysis and early warning.
The Ministry of Commerce has organized some large drug wholesale and retail enterprises to pay close attention to the supply and demand situation of key drugs.
Strengthen departmental linkage and ensure the stable supply of shortage drugs throughout the entire chain.
The four-level response system for shortages of drugs at the national, provincial, city, and county levels has gradually been improved and effectively operated. Information on reported shortages of drugs in 2023 has been fully responded to, and the temporary import of urgently needed clinical drugs has been properly implemented.
The State Food and Drug Administration continues to promote the review and approval of varieties on the national shortage drug list, and carries out basic information labeling and data management of shortage drugs.
The National Medical Insurance Administration has fully implemented the online procurement policy for shortages of drugs and explored centralized and bulk procurement of shortages of drugs.
The Ministry of Industry and Information Technology continues to support the construction of centralized production bases for small varieties of drugs, and establishes central and local level reserves of regularly in short supply drugs.
The Ministry of Ecology and Environment will adopt flexible law enforcement in accordance with the law for environmental violations involving shortages of pharmaceutical raw materials or preparation manufacturers, and help companies make timely rectifications.
The State-owned Assets Supervision and Administration Commission of the State Council continues to promote state-owned enterprises to fulfill their social responsibilities in supplying medicines in shortage and to play their "reservoir" function.
The State Post Bureau continues to promote the construction of a comprehensive postal service platform and supports postal groups to leverage their network advantages to continuously improve their pharmaceutical delivery service capabilities.
Maintain market order and strengthen law enforcement for violations of laws and regulations.
The State Administration for Market Regulation investigates and handles illegal activities such as monopoly in the pharmaceutical field in accordance with the law, and plays a warning and educational role in major typical cases.
The State Administration of Taxation has further stepped up its efforts to investigate and punish tax-related illegal activities of some pharmaceutical companies and standardize taxation order in the pharmaceutical field.
Based on clues to the problem and illegal facts, the National Medical Insurance Administration interviewed relevant pharmaceutical companies to reduce the price levels of the drugs involved and block the interest chain of manufacturing shortages and monopoly price increases.